INVESTOR NEWS

Mar 30, 2023

Annual report 2022

Mar 22, 2023

Health economic model identifies GCAL® as a cost-effective biomarker

Moss, 22 March 2023

Mar 17, 2023

Financial calendar

Financial calendar for Gentian Diagnostics ASA

Feb 16, 2023

Fourth quarter and full year 2022 report

Moss, 16 February 2023

Feb 15, 2023

New study addresses the use of plasma calprotectin in sepsis management

Moss, 15 February 2023

Feb 10, 2023

Invitation to presentation of fourth quarter results

Gentian Diagnostics ASA will present its fourth quarter 2022 results on February 16th at 10.00 am.

Dec 15, 2022

Mandatory notification of trade

Moss, 15 December 2022

Dec 14, 2022

Gentian Diagnostics appoints new CSO

Moss, 14 December 2022

Dec 13, 2022

Financial calendar

Financial calendar for Gentian Diagnostics ASA

Dec 05, 2022

Patent granted for NT-proBNP in the U.S.

Moss, 5 December 2022